Leveraging Cognitive Neuroscience Research to Improve Assessment of Cancer Treatment Related Cognitive Impairment (R01)

Post Date

April 21st 2016

Application Due Date

April 11th 2019

Funding Opportunity Number

PAR-16-212

CFDA Number(s)

93.395

Funding Instrument Type(s)

Grant

Funding Activity Categories

Education
Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Award Range:

  $None - $None

Grant Description

This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as chemobrain. A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/pa-files/PAR-16-212.html